Inventarisasi Kepiting Air Tawar di Kecamatan Kampar Utara Kabupaten Kampar Provinsi Riau

Freshwater crab is widely distributed in river, lake, swamp, canal, and pond. Riau Province has many freshwater crabs, however biological information of these organisms are poorly known. This study aimed to understand the freshwater crab types from the Kampar Utara District, Riau Province. Samples from 14 sampling sites, in the Sawah, Sendayan and Sungai Jalau village had been collected from March to April 2013 using bamboo traps and scoop net. There were 178 crabs captured and all of them belonged to a single genus, Parathelpusa. Numbers of crab were obtained from the shallow riverines with numerous aquatic vegetation and no crab caught in the rivers. Based on the results, it can be concluded that the habitat of Parathelpusa in Riau is shallow riverine with dense aquatic vegetation

Generic results of the space physics community survey

This report summarizes the results of a survey of the members of the space physics research community conducted in 1990-1991 to ascertain demographic information on the respondents and information on their views on a number of facets of their space physics research. The survey was conducted by questionnaire and the information received was compiled in a database and analyzed statistically. The statistical results are presented for the respondent population as a whole and by four different respondent cross sections: individual disciplines of space physics, type of employers, age groups, and research techniques employed. Data from a brief corresponding survey of the graduate students of respondents are also included

Potensi Dan Nilai Ekonomi Cadangan Karbon Di Hutan Pendidikan Dan Pelatihan Pondok Buluh

This study aimed to determine the type of tree vegetation, carbon stocks, and its economic vale in experimental forest of Pondok Buluh, Simalungun District, North Sumatra. It was conducted from April to May 2014. The collection of data used path method, and the sampling technique used Purpose sampling with random start method. The plot size by 20 m × 100 m consist of 10 plots categorized as large plot in observation of trees with diameter > 30 cms and there was small plot within by 5 m × 40 m to observe the tree with diameter 5 cms to < 30 cms. The collection of data performed by non-destructive method with biomass data analysis using allometric models with a carbon content 0f 46% of biomass. The results of study shown that 49 species of trees derived from 25 families. Carbon content stored on observation plots 173,40 tons/ha, and estimation of total carbon stocks 190.737,70 tons. The economic value carbon stock above ground biomass of standing tree in Education Forest of Pondok Buluh around IDR 33.474.466.350,00 to IDR 44.632.621.800,00

Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma

BACKGROUND: Cancer patients with advanced disease routinely exhaust available clinical regimens and lack actionable genomic medicine results, leaving a large patient population without effective treatments options when their disease inevitably progresses. To address the unmet clinical need for evidence-based therapy assignment when standard clinical approaches have failed, we have developed a probabilistic computational modeling approach which integrates molecular sequencing data with functional assay data to develop patient-specific combination cancer treatments. METHODS: Tissue taken from a murine model of alveolar rhabdomyosarcoma was used to perform single agent drug screening and DNA/RNA sequencing experiments; results integrated via our computational modeling approach identified a synergistic personalized two-drug combination. Cells derived from the primary murine tumor were allografted into mouse models and used to validate the personalized two-drug combination. Computational modeling of single agent drug screening and RNA sequencing of multiple heterogenous sites from a single patient's epithelioid sarcoma identified a personalized two-drug combination effective across all tumor regions. The heterogeneity-consensus combination was validated in a xenograft model derived from the patient's primary tumor. Cell cultures derived from human and canine undifferentiated pleomorphic sarcoma were assayed by drug screen; computational modeling identified a resistance-abrogating two-drug combination common to both cell cultures. This combination was validated in vitro via a cell regrowth assay. RESULTS: Our computational modeling approach addresses three major challenges in personalized cancer therapy: synergistic drug combination predictions (validated in vitro and in vivo in a genetically engineered murine cancer model), identification of unifying therapeutic targets to overcome intra-tumor heterogeneity (validated in vivo in a human cancer xenograft), and mitigation of cancer cell resistance and rewiring mechanisms (validated in vitro in a human and canine cancer model). CONCLUSIONS: These proof-of-concept studies support the use of an integrative functional approach to personalized combination therapy prediction for the population of high-risk cancer patients lacking viable clinical options and without actionable DNA sequencing-based therapy

Gender, hormone therapy, and HIV: what should cardiologists know?

Transgender individuals represent the fastest growing minority in the United States and are disproportionately affected by HIV. Hormone therapy is the most common treatment for gender dysphoria in transgender individuals. As HIV is an independent risk factor for coronary artery disease, it is critical to further research the influence masculinising and feminising hormone therapies have on cardiovascular disease. There is a clinical need for evidence-based guidelines for cardiologists to follow to effectively care for and treat transgender patients. For this to be done, the interplay between HIV, hormone therapy, and cardiovascular disease must be better understood through collaboration between researchers and clinicians to achieve maximum benefit from recent advancements

Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies

A universal influenza candidate vaccine that targets multiple conserved influenza virus epitopes from hemagglutinin (HA), neuraminidase (NA) and matrix (M2e) proteins was combined with the potent Army liposomal adjuvant (ALFQ) to promote induction of broad immunity to seasonal and pandemic influenza strains. The unconjugated and CRM-conjugated composite peptides formulated with ALFQ were highly immunogenic and induced both humoral and cellular immune responses in mice. Broadly reactive serum antibodies were induced across various IgG isotypes. Mice immunized with the unconjugated composite peptide developed antibody responses earlier than mice immunized with conjugated peptides, and the IgG antibodies were broadly reactive and neutralizing across Groups 1 and 2 influenza viruses. Multi-epitope unconjugated influenza composite peptides formulated with ALFQ provide a novel strategy for the development of a universal influenza vaccine. These synthetic peptide vaccines avoid the pitfalls of egg-produced influenza vaccines and production can be scaled up rapidly and economically

Unconjugated Multi-Epitope Peptides Adjuvanted with ALFQ Induce Durable and Broadly Reactive Antibodies to Human and Avian Influenza Viruses

An unconjugated composite peptide vaccine targeting multiple conserved influenza epitopes from hemagglutinin, neuraminidase, and matrix protein and formulated with a safe and highly potent adjuvant, Army Liposome formulation (ALFQ), generated broad and durable immune responses in outbred mice. The antibodies recognized specific epitopes in influenza peptides and several human, avian, and swine influenza viruses. Comparable antibody responses to influenza viruses were observed with intramuscular and intradermal routes of vaccine administration. The peptide vaccine induced cross-reactive antibodies that recognized influenza virus subtypes A/H1N1, A/H3N2, A/H5N1, B/Victoria, and B/Yamagata. In addition, immune sera neutralized seasonal and pandemic influenza strains (Group 1 and Group 2). This composite multi-epitope peptide vaccine, formulated with ALFQ and administered via intramuscular and intradermal routes, provides a high-performance supra-seasonal vaccine that would be cost-effective and easily scalable, thus moving us closer to a viable strategy for a universal influenza vaccine and pandemic preparedness

Supplementary Material for: X-linked lymphoproliferative syndrome: a spectrum of clinical and immunological profile and novel pathogenic variants from Chandigarh, India

Introduction: X-linked lymphoproliferative syndrome (XLP) is a rare primary immune deficiency. Two types of XLP have been described: XLP-1 and XLP-2. Methods: We found 7 patients with XLP (3 had XLP-1 and 4 had XLP-2) after reviewing the data from Pediatric Immunodeficiency Clinic from 1997-2021. Results: Mean age at diagnosis was 3.8 years and mean delay in diagnosis was 2.6 years. Five patients had recurrent episodes of infections. Four patients developed at least one episode of hemophagocytic lymphohistiocytosis (HLH) (2 with XLP-1 and 2 with XLP-2). Of these, 2 had recurrent HLH (both with XLP-2). Epstein-Barr virus (EBV) infection was detected in 2 (1 with XLP-1 and 1 with XLP-2). Both these patients had HLH. One child with XLP-2 had inflammatory bowel disease. Hypogammaglobulinemia was seen in 3 (2 with XLP-1 and 1 with XLP-2). Genetic analysis showed previously reported variants in 5, while 2 had novel variants (one in exon 7 of XIAP gene [c.1370dup p. Asn457Lysfs Ter16] and other had splice site variant in intron 1 of SH2D1A gene [c.138-2_138-1insG]). Episodes of HLH were managed with intravenous immunoglobulin (IVIg), methylprednisolone, oral prednisolone, cyclosporine and rituximab. Inflammatory bowel disease was managed using oral prednisolone and azathioprine. One patient underwent haploidentical hematopoietic stem cell transplantation (HSCT). One child with XLP-2 and WAS died because of fulminant pneumonia. Discussion/Conclusions: XLP should be considered as a strong possibility in any patient with features of HLH, repeated infections with hypogammaglobulinemia, persistent EBV infection and early onset IBD